+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Carbamylated Hemoglobin in Prerenal Azotemia

      , ,


      S. Karger AG

      Azotemia, prerenal, Carbamylated hemoglobin, Valine hydantoin

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Carbamylated hemoglobin (Carb Hb) levels were measured in 16 patients with a documented transient rise in BUN due to prerenal azotemia, in whom BUN levels before and after the episode were normal. They were compared with 13 controls. Carb Hb was expressed as carbamyl valine concentrations, which were significantly higher in the patients (166 μg/g Hb) than in controls (95.3 μg/g Hb, p < 0.01). The mean maximum BUN level in the patients was 51.8 ± 23.9 mg/dl. There was a significant correlation between the product of mean BUN level times the number of days of BUN elevation, and the Carb Hb level (r = 0.5197; p < 0.05). There was no correlation between Carb Hb and either mean BUN level or maximum BUN level. Elevated Carb Hb was seen after a minimum of 4 days’ BUN elevation. Four patients had no elevation of Carb Hb despite elevated BUN levels. Conclusion: Carb Hb may be elevated after a minimum of 4 days’ transient BUN elevation; Carb Hb is not useful in differentiating between mild acute renal failure and prerenal azotemia.

          Related collections

          Author and article information

          S. Karger AG
          18 December 2008
          : 71
          : 2
          : 153-155
          Department of Nephrology, Department of Veterans Affairs Medical Center, Brooklyn, State University of New York Health Science Center at Brooklyn and St. John’s Episcopal Hospital, Far Rockaway, New York, N.Y., USA
          188704 Nephron 1995;71:153–155
          © 1995 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 3
          Original Paper

          Cardiovascular Medicine, Nephrology

          Valine hydantoin, Carbamylated hemoglobin, Azotemia, prerenal


          Comment on this article